These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34597713)

  • 1. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Campochiaro PA; Chang MA; Miller D; Pieramici D; Adamis AP; Brittain C; Evans E; Kaufman D; Maass KF; Patel S; Ranade S; Singh N; Barteselli G; Regillo C;
    Ophthalmology; 2022 Mar; 129(3):295-307. PubMed ID: 34597713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.
    Regillo C; Berger B; Brooks L; Clark WL; Mittra R; Wykoff CC; Callaway NF; DeGraaf S; Ding HT; Fung AE; Gune S; Le Pogam S; Smith R; Willis JR; Barteselli G
    Ophthalmology; 2023 Jul; 130(7):735-747. PubMed ID: 36870451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Khanani AM; Callanan D; Dreyer R; Chen S; Howard JG; Hopkins JJ; Lin CY; Lorenz-Candlin M; Makadia S; Patel S; Tam T; Gune S;
    Ophthalmol Retina; 2021 Aug; 5(8):775-787. PubMed ID: 33217618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
    Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
    Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
    JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
    Campochiaro PA; Marcus DM; Awh CC; Regillo C; Adamis AP; Bantseev V; Chiang Y; Ehrlich JS; Erickson S; Hanley WD; Horvath J; Maass KF; Singh N; Tang F; Barteselli G
    Ophthalmology; 2019 Aug; 126(8):1141-1154. PubMed ID: 30946888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
    Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Chang MA; Kapre A; Kaufman D; Kardatzke DR; Rabena M; Patel S; Bobbala A; Gune S; Fung A; Wallenstein G
    JAMA Ophthalmol; 2022 Aug; 140(8):771-778. PubMed ID: 35708706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.
    Kertes PJ; Galic IJ; Greve M; Williams G; Baker J; Lahaie M; Sheidow T
    JAMA Ophthalmol; 2020 Mar; 138(3):244-250. PubMed ID: 31917441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
    Khanani AM; Patel SS; Ferrone PJ; Osborne A; Sahni J; Grzeschik S; Basu K; Ehrlich JS; Haskova Z; Dugel PU
    JAMA Ophthalmol; 2020 Sep; 138(9):964-972. PubMed ID: 32729897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
    JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration.
    Waldstein SM; Coulibaly L; Riedl S; Sadeghipour A; Gerendas BS; Schmidt-Erfurth UM
    Br J Ophthalmol; 2020 Jul; 104(7):899-903. PubMed ID: 31563866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
    Silva R; Berta A; Larsen M; Macfadden W; Feller C; Monés J;
    Ophthalmology; 2018 Jan; 125(1):57-65. PubMed ID: 28893454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
    Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
    Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
    Khurana RN; Rahimy E; Joseph WA; Saroj N; Gibson A; Vitti R; Berliner AJ; Chu K; Cheng Y; Boyer DS
    Am J Ophthalmol; 2019 Apr; 200():161-168. PubMed ID: 30664844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.